Has Halle Berry confirmed she uses HRT?

Yes. Berry has confirmed in congressional testimony and multiple interviews that she uses hormone therapy to manage menopausal symptoms. She has not disclosed the specific type, dose, or brand of HRT she uses.

What is Respin, and how does it relate to menopause?

Respin is Halle Berry's wellness platform. It includes a health vertical focused on menopause education, symptom management resources, and advocacy for expanded insurance coverage of menopausal treatments.

Is HRT safe for menopausal women?

For symptomatic women under 60 or within 10 years of menopause onset, current guidelines from The Menopause Society state that the benefits of HRT generally outweigh the risks. Individual risk factors (clotting history, breast cancer risk, cardiovascular status) should be evaluated with a qualified provider.

What types of HRT are available?

HRT comes in oral tablets, transdermal patches, topical gels, vaginal rings, creams, and pellet implants. The choice of formulation depends on the patient's symptoms, risk profile, and preferences. Transdermal routes may carry lower clotting risk than oral formulations.

Did Halle Berry testify before Congress about menopause?

Yes. In 2023, Berry testified before the U.S. Senate in support of the Advancing Menopause Care and Mid-Life Women's Health Act, which proposed increased NIH funding for menopause research and expanded clinician training.

Halle Berry and Women's HRT: The Documented Public Record

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Halle Berry and Women's HRT: The Documented Public Record Image: HealthRX.com clinical image

Halle Berry's Public Record on HRT and Menopause

Halle Berry's relationship with menopause care became part of the public record long before she launched a wellness brand around it. In 2023, Berry testified before the U.S. Senate in support of the Advancing Menopause Care and Mid-Life Women's Health Act, telling lawmakers she had been "in menopause for a number of years" and describing the confusion she experienced when symptoms first appeared. During the hearing, she confirmed that she had sought medical treatment, including hormone therapy, after initially being misdiagnosed.

Berry has repeated this account across multiple public appearances. In a 2023 interview with CNN, she described being told by a doctor that she was "in menopause" in her early 40s and subsequently working with her medical team to find treatments that worked for her body. She has referenced hormone therapy specifically, though she has not disclosed the exact formulations, doses, or brands she uses.

Her platform Respin (originally re-spin) launched with a health vertical that centers menopause education. Berry has used Respin and her social media channels to advocate for insurance coverage of menopausal treatments and to push back against what she calls the stigma of aging in women.

At a glance

Status: Confirmed. Halle Berry has publicly stated she uses HRT for menopause management.
Public timeline: Symptoms reportedly began in her early 40s. Congressional testimony and media interviews from 2023 onward confirm she sought and received treatment, including hormone therapy.
Specific medications: Not publicly disclosed. Berry has confirmed the category (hormone therapy) without naming products, doses, or delivery methods.
Platform: Founded Respin, a wellness brand with a dedicated menopause content vertical. Testified before the U.S. Senate in support of menopause research funding.

What Is Menopausal HRT? The Clinical Basics

Hormone replacement therapy for menopause typically involves supplementing estrogen, progesterone, or both to offset the decline in ovarian hormone production that occurs during the menopausal transition. The goal is symptom relief: hot flashes, night sweats, vaginal dryness, sleep disruption, and mood changes are among the most common complaints that bring women to treatment.

For women with an intact uterus, estrogen is prescribed alongside a progestogen (either micronized progesterone or a synthetic progestin) to protect the uterine lining from estrogen-driven overgrowth. Women who have had a hysterectomy can take estrogen alone. Delivery methods include oral tablets, transdermal patches, topical gels, vaginal rings, and vaginal creams, each with a distinct pharmacokinetic profile.

The 2022 Hormone Therapy Position Statement from The Menopause Society (formerly NAMS) reaffirmed that for symptomatic women under 60 or within 10 years of menopause onset, the benefits of HRT generally outweigh the risks. This "timing hypothesis" has been supported by data from the WHI reanalysis and subsequent observational studies showing that early initiation is associated with reduced cardiovascular risk compared to late initiation.

Why Berry's Advocacy Matters Clinically

Berry's public story tracks a pattern the HealthRX.com Medical Team sees frequently in clinical literature: delayed diagnosis. A 2024 survey published in Menopause found that nearly 75% of menopausal women reported feeling their symptoms were dismissed or misattributed by a healthcare provider at least once. Berry herself has stated publicly that her early perimenopausal symptoms were initially attributed to other causes before a correct diagnosis was made.

The HealthRX.com Medical Team considers this a critical access problem. When a high-profile figure describes the same diagnostic delays that appear in the literature, it reinforces a systemic issue: many clinicians receive minimal formal training in menopause management. A 2021 study found that only 20% of OB-GYN residency programs in the United States offered a menopause medicine curriculum.

Berry's congressional testimony put a specific policy ask behind the personal story. The Advancing Menopause Care and Mid-Life Women's Health Act, which she endorsed, proposed dedicated NIH funding for menopause research and expanded provider education. Regardless of the bill's legislative trajectory, the public attention it drew to HRT access reflects a measurable shift in how menopause care is discussed at the policy level.

Confirmed vs. Speculated: Drawing the Line

What Berry has confirmed:

She experienced perimenopausal and menopausal symptoms beginning in her early 40s.
She was initially misdiagnosed.
She uses hormone therapy as part of her menopause management.
She founded Respin with menopause awareness as a core pillar.
She testified before Congress in support of menopause care legislation.

What remains unconfirmed or speculated:

The specific HRT formulation she uses (estradiol patch, oral estrogen, compounded bioidentical, or another form) has not been publicly disclosed.
Her dosing regimen, treatment duration, and whether she uses a combined estrogen-progestogen protocol or estrogen alone are not part of the public record.
Whether she uses any adjunctive treatments (vaginal estrogen, DHEA, testosterone) has not been stated publicly.

The HealthRX.com Medical Team notes that Berry's choice to disclose the category without disclosing the specifics is both common and reasonable. Medication regimens are personalized. What works for one woman depends on her symptom profile, medical history, risk factors, and preferences, and public figures are under no obligation to share clinical details.

The Risk-Benefit Conversation: What the Evidence Shows

HRT remains the most effective treatment for vasomotor symptoms (hot flashes and night sweats), reducing their frequency by 75% or more in most clinical trials. It also improves sleep quality, vaginal and urogenital symptoms, and, in some women, mood and cognitive complaints during the transition.

The risk profile depends on the type, dose, route, and timing of therapy. Key considerations from current evidence:

Breast cancer: Combined estrogen-progestogen therapy is associated with a small increase in breast cancer risk after approximately 5 years of use. Estrogen-only therapy in women with prior hysterectomy showed no increased risk (and a possible decreased risk) in the WHI extended follow-up.
Cardiovascular: For women initiating HRT within 10 years of menopause onset, coronary heart disease risk does not increase and may decrease. Late initiation (after age 60 or >10 years post-menopause) carries higher cardiovascular risk.
Venous thromboembolism (VTE): Oral estrogen carries a higher VTE risk than transdermal estrogen. The ESTHER study and subsequent analyses suggest transdermal delivery largely avoids the clotting risk associated with oral formulations.
Bone health: HRT is FDA-approved for osteoporosis prevention and reduces hip and vertebral fractures. This benefit is maintained for the duration of use.

The HealthRX.com Medical Team emphasizes that these population-level statistics are starting points. Individual risk stratification, factoring in family history, BMI, smoking status, and existing cardiovascular or clotting risk, determines whether HRT is appropriate for a given patient.

What Berry's Story Tells Us (and What It Doesn't)

Halle Berry's public advocacy has done something measurable: it brought menopause into a policy conversation it was largely absent from. Her personal confirmation of HRT use normalized a treatment that millions of women use but few public figures discuss openly.

What her story cannot do is serve as a clinical recommendation. Berry's regimen is her own, designed with her own medical team for her own body. The HealthRX.com Medical Team's position is straightforward: if you are experiencing perimenopausal or menopausal symptoms, the evidence supports having a direct conversation with a menopause-trained provider about whether HRT is appropriate for you. Organizations like The Menopause Society maintain a certified practitioner directory for exactly this purpose.

Celebrity disclosures open doors. Clinical evidence walks through them.

Frequently asked questions

›